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OBJECTIVES: Survival data for young adults (YA) with gastric cancer is conflicting and scarce in Brazil. The aim
of this study was to compare the clinicopathological factors and survival rates of younger and older patients
with gastric cancer.
METHODS: Hospital registries for 294 gastric cancer patients from a reference cancer hospital in Sa˜o Paulo,
Brazil, were consulted for the retrieval of clinicopathological information and follow-up time. Patients were
placed into the following groups: YA (p40 years; N=71), older adult (OA: 41 to 65 years; N=129) and elderly
(E: X66 years; N=94). Differences were assessed through Pearson’s w2 test, Kaplan-Meier analysis, Log rank test
and Cox regression.
RESULTS: More YA were diagnosed with advanced disease (clinical stage III/IV: 86.7% YA, 69.9% OA, and 67% E);
however, fewer E patients underwent surgery (64.3% YA, 72.7% OA, and 52.4% E). The median overall survival
among all patients was 16 months, and the overall survival rate was not significantly different among the age
groups (p=0.129). There were no significant differences in the disease-free survival rate. Metastatic disease at
diagnosis (HR=4.84; po0.01) was associated with an increased hazard of death for YA.
CONCLUSION: Overall survival was similar among age groups. Metastatic disease at diagnosis was the only
factor associated with a poorer prognosis in YA. These results suggest that younger patients deserve special
attention regarding the detection of early stage disease.
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’ INTRODUCTION
Gastric cancer is the fifth most common cancer worldwide
and is one of the deadliest types, accounting for 723,000
deaths worldwide in 2012 (1). Although global gastric
cancer incidence and mortality rates have been declining
worldwide, an increased or flattened incidence rate has
been observed in young patients (2,3). In a study performed
in the USA, the gastric cancer incidence among white adults
aged 25 to 39 years increased from 0.27 per 100,000 person-
years in 2002 to 0.45 in 2006 (2). However, there are con-
flicting findings with respect to the survival of young
patients. While some studies have reported lower survival
rates in this age group (4,5), others have reported a better
prognosis compared to older individuals (6,7), and some
still have described no differences in survival based on
age (8,9).
In Brazil, 20,000 new gastric cancer cases were expected in
2016 (10). This type of cancer remains the second leading
cause of cancer-related death in our country, accounting for
14,182 deaths in 2013 (11). Although only scarce data are
available in Brazil, stomach cancer incidence and mortality
trends appear to be declining, similar to what is observed in
other countries (12-14). In São Paulo state, which comprises
almost 22% of the Brazilian population, there is evidence that
the stomach cancer age-specific incidence rate is falling in
all age groups, except in young female adults, in whom
it apparently has attained a steady state (15). Regarding
mortality, a recent study reported that mortality rates have
markedly increased in patients agedo50 years compared to
older patients over a 5-year period (13).
Recently, there has been increasing interest in characteriz-
ing cancers that affect adolescents and young adults (YAs).
According to the definition of the NCI Progress Review Group,
this age group comprises individuals aged 15-39 years (16);
however, cut-off limits considered in various types of cancer
range from 40 to 50 years (17). In adolescents and YAs, cancer
is associated with high physical and psychological morbidity.
Nevertheless, only a few studies have focused on cancer in this
specific population, and many questions remain regarding
carcinogenesis, prognosis and treatment.DOI: 10.6061/clinics/2018/e651s
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ORIGINAL ARTICLE
Previous studies demonstrated that early age of gastric
cancer onset may be associated with some clinicopathological
particularities. Females are more frequent among younger
patients (in all-age stomach cancer, the male to female ratio is
2:1), and diffuse and undifferentiated histologic types are more
frequently diagnosed in younger patients than in older people
(in whom the intestinal type is more frequent) (4-7,18). More-
over, young people usually present with disease at a more
advanced stage (4-6).
In Brazil, a study investigating differences between younger
and older gastric cancer patients included 39 individuals aged
o45 years and found a higher incidence of diffuse-type gastric
cancer and a female preponderance in the younger age group
(19). Our research group is also involved in evaluating lifestyle
factors that may be associated with gastric cancer. Previously,
we have found that compared to older patients, those aged
o55 years usually have greater ingestion of red and processed
meat, both considered risk factors for gastric cancer develop-
ment (manuscript submitted for publication). To the best of our
knowledge, no study has explored survival and clinicopatho-
logical features simultaneously according to age in Brazil.
Therefore, gastric cancer is still a major cause of concern in
our country, and only scarce data are available regarding
clinical characteristics and survival for the subgroup of YAs.
Thus, our aim was to compare the clinicopathological features
and survival of younger and older patients with gastric
cancer in a reference cancer hospital in São Paulo, Brazil.
These data may contribute to distinguishing whether YAs
have special needs requiring specific care.
’ MATERIALS AND METHODS
Patients
This observational retrospective study was conducted
at Instituto do Câncer do Estado de São Paulo (ICESP) in
São Paulo city, Brazil. São Paulo is the largest city in
Brazil, and its metropolitan area has more than 20 million
people (20). ICESP draws from the Brazilian public health
network (SUS, Sistema Único de Saúde), which is respon-
sible for delivering health care to nearly 34 of our population,
representing approximately 150 million people (21). ICESP
is the largest reference hospital for cancer treatment in
Latin America and delivers care to approximately 10% of
São Paulo state gastric cancer patients referred from primary
and secondary care (22). This study was approved by the
Institutional Ethics Committee (Comitê de Ética em Pesquisa
da Faculdade de Medicina da Universidade de São Paulo,
protocol no 48390115.2.0000.0065).
The inclusion criteria were as follows: 1) diagnosis of
gastric carcinoma according to the World Health Organization
International Classification of Diseases (WHO - ICD 16) and
2) registry date at ICESP between January 2011 and December
2013. The exclusion criteria were 1) gastric carcinoma diag-
nosis before 2010 or after 2013 and 2) diagnosis of malignant
neoplasia of the stomach not otherwise specified (ICD 16.9).
Because age limits for both YAs and elderly (E) people are
not internationally defined, cut-offs were set at 40 years for
YAs, as reported in similar previous studies (4,6,8,9), and at
65 years for E patients, as is commonly used in Brazil.
During the study period, 1209 patients were registered at
our hospital for investigation or treatment of gastric cancer,
and all of them were assessed for eligibility. Of these, the
hospital registries of 84 patients (6.9%) who were 40 years
old or younger were reviewed. From the remaining 1125
patients, we randomly selected 3 controls for each patient
using the Microsoft Excelt 2016 function ‘‘RANDBETW-
EEN’’ and thus included 252 older patients for data collection
and analysis.
After reviewing the patients’ files, eleven young patients and
31 older patients were excluded based on the exclusion criteria.
Figure 1 - Flowchart of patient selection.
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Moreover, two young patients were reclassified to the
older group after correcting their date at diagnosis. Finally,
patients diagnosed at 40 years or younger were considered
YA (N=71), and the remaining 223 patients were divided
into older adult (OA; N=129), aged 41 to 65 years old,
and E (N=94), aged 66 or older. Figure 1 summarizes patient
selection.
Clinicopathological information, including sex, age at
diagnosis, diagnostic method, histological type according
to Lauren classification (23), TNM classification (24), date of
recurrence, date of death and whether the patient under-
went curative surgery and received chemotherapy, were
retrieved from the hospital registry. Lifestyle factors were not
evaluated because such data were missing for most patients.
For overall survival, follow-up time was calculated from the
date of diagnosis to the date of death or of last hospital
registry until December 2016. Diagnostic methods were as
follows: 1) stomach biopsy before surgery (86.4% of cases);
2) pathology report of gastric surgery (8.8%); 3) biopsy of
metastatic sites or fine needle aspiration of primary tumor
site (1.7%); 4) computed tomography of inoperable meta-
static disease (2.6%); and 5) not reported (0.3%). Histological
classification was reviewed by a pathologist before analysis.
Statistical analysis
Clinicopathological features were compared among groups
using the Pearson w2 test. Overall survival was estimated
with the Kaplan-Meier method, and differences were asses-
sed using the log rank test. A Cox regression model was used
to estimate hazard ratios of variables in the univariate analysis;
significant variables were included in the multivariate Cox
model. P-values o0.05 indicated statistical significance. Statis-
tical analysis was performed with SPSS version 20.
’ RESULTS
Clinicopathological characteristics
Seventy-one (24.14%) out of 294 patients were 40 years old
or younger, 129 (43.87%) were from 41 to 65 years old,
and 94 (31.97%) were 66 years old or older at the times of
gastric cancer diagnosis. There was a trend toward a higher
female to male ratio in the YA group (1.08:1) than in the OA
(0.61:1) and E groups (0.7:1). Among patients with available
Lauren histological classification, diffuse-type tumors were
predominant in the YA (90.16%) and OA groups (53.92%)
and less common in the E group (29.68%); however, there
were high rates of missing data in all groups (YA 14.1%; OA
20.9%; E 31.9%). Although most patients in all age groups
were diagnosed at an advanced clinical stage (CS III or IV),
this proportion in the YA group was significantly higher
(YA 88.7%; OA 69.9%; E 67.1%; p=0.009). Moreover, the
lowest rates of surgery (48.9%) and chemotherapy (17.2%)
were observed in the E group. This data is summarized in
Table 1.
Overall survival
For all 294 patients, the mean and median follow-up were
20.65 and 14 months, respectively, and the estimated mean
and median overall survival were 28.58 and 16 months, res-
pectively. For the YA, OA and E groups, the mean overall
survival was 24.99, 31.80 and 25.57 months, and the median
survival was 15, 21 and 12 months, respectively. There were
no significant differences in overall cumulative survival
among groups (p=0.129), but the OA group tended to have
the best outcome. The two-year survival rates were 31%,
45.9%, and 35.1% in the YA, OA and E groups, respectively.
Figure 2a shows the Kaplan-Meier survival curve for all clinical
stages for each group.
To analyze cumulative survival according to CS, patients
were divided into the early stage disease (CS 0 and I), locally
advanced disease (CS II and III) and metastatic disease
groups (CS IV). Figures 2b and 2c show the Kaplan-Meier
survival curves for patients in the early stage and locally
advanced disease groups, respectively, according to age
group. There were no significant differences in survival.
Figure 2d shows the Kaplan-Meier survival curve for
patients in the metastatic disease group; among these
patients, the E group had a significantly poorer outcome.
Table 2 summarizes the cumulative 2-year survival rate for
each group.
Disease-free survival
For the disease-free survival analysis, we included 142
patients (YA N=31; OA N=75; E N=36) who underwent
curative surgery. Follow-up time was calculated from the
surgery date to the date of recurrence or death. There were
no significant differences in disease-free survival, although
Table 1 - Clinicopathological features of gastric cancer patients according to age group.
Characteristic Younger Adult (p40 years) N=71 Older Adult (41 to 65 years) N=129 Elderly (465 years) N=94 P-value
Age at diagnosis (years)
Median 37 57 73
Gender
Female 37/71 (52.1%) 49/129 (38.0%) 39/94 (41.5%) 0.15
Histology
Intestinal 3/61 (4.9%) 39/102 (38.2%) 39/64 (60.9%) o0.01*
Diffuse 57/61 (90.2%) 55/102 (54.0%) 19/66 (29.7%)
Mixed 3/61 (4.9%) 8/102 (7.8%) 6/64 (9.4%)
Clinical stage
0 or I 4/68 (5.9%) 20/123 (16.3%) 15/82 (18.3%) o0.01*
II 5/68 (7.4%) 17/123 (13.8%) 12/82 (14.6%)
III 23/68 (33.8%) 40/123 (32.5%) 12/82 (14.6%)
IV 36/68 (52.9%) 46/123 (37.4%) 43/82 (52.4%)
Surgery 45/70 (64.3%) 93/128 (72.7%) 43/88 (48.9%) o0.01*
Chemotherapy 21/70 (30%) 44/124 (35.5%) 15/87 (17.2%) 0.01*
*Statistically significant
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the E group tended to have a better outcome. Figure 3a-c and
Table 2 summarize the results.
Prognostic factors
In the univariate analysis with all patients, diffuse-type
tumors, CS, no surgery and no chemotherapy were signifi-
cantly associated with an increased hazard ratio of death.
Locally advanced and metastatic didease at diagnosis and no
chemotherapy remained significant in the multivariate analysis.
Prognostic factors exclusive for YAs were also evaluated.
The multivariate analysis demonstrated that CS IV at diagnosis
was the only factor significantly associated with an increased
hazard ratio for death in this group. Table 3 summarizes
these findings.
Table 2 - Two-year cumulative survival rate (%).
Younger Adult
(p40 years)
Older Adult
(41 to 65 years)
Elderly
(465 years)
Overall survival N=71 N=129 N=94
All 31 45.9 35.1
Clinical stage
0 or I 100 80 86.7
II or III 56.2 53.1 65.5
IV 3.1 12.7 5.3
Disease-free survival N=31 N=75 N=36
All 49.2 59.2 73.1
Clinical stage
0 or I 80 90.9 90
II or III 42.9 47.5 65.5
Figure 2 - Overall survival. (2a) Overall survival according to patient age group. (2b) Overall survival in clinical stages 0 and I according
to patient age group (YA N=4; OA N=20; E N=15). (2c) Overall survival in clinical stages II and III according to patient age group (YA
N=28; OA N=57; E N=24). (2d) Overall survival in clinical stage IV according to patient age group (YA N=36; OA N=46; E=43).
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’ DISCUSSION
Cancer is usually caused by cumulative genetic mutations
and epigenetic alterations; therefore, it is more common in
older individuals. For gastric cancer, the majority of patients
are diagnosed after 60 years of age. Nevertheless, the stomach
cancer incidence among younger individuals appears to be
increasing (2,3), and recent studies have reported conflicting
results regarding survival in this set of patients (5,6,9).
To analyze whether there are differences in survival and
prognostic factors between younger and older patients with
gastric cancer in Brazil, this retrospective cohort study
with 294 patients from the country’s largest cancer center
was designed.
In this study, there was a higher proportion of women
among the younger patients (52.1% in YA, 38% in OA and
41.5% in E), which is in agreement with the findings of
previous reports (4-9,13,18). Although the reasons for this
difference are not clear, two potential explanations have been
identified so far. First, men are more frequently exposed
to known gastric cancer risk factors, such as smoking and
alcohol intake, which might contribute to increased gastric
cancer incidence later in life. Second, a decreased risk of
stomach cancer was associated with longer years of fertility
and postmenopausal hormone replacement therapy (25-27).
As women aged 40 or younger might not have benefited
from these protective factors, the incidence rates of males
and females in younger groups of patients tend to equalize.
Several studies, including those performed in Brazil, found
that the diffuse histological subtype is more commonly
detected in younger individuals (4-9,13,18). In our study,
93.4% of the younger patients for whom detailed histological
information was available presented with this subtype of
cancer. Germline mutations, specifically in the CDH1 gene,
associated with gastric cancer diagnosis at a younger age and
with a diffuse phenotype might have contributed to this dis-
proportion. In Brazil, a previous study of individuals with a
family history of gastric cancer found CDH1 germline patho-
genic mutations in 2 of 4 families (28). Nevertheless, our
group did not find any pathogenic mutations in the CDH1
gene in a group of Brazilian individuals agedo55 years with
gastric cancer. The pathogenesis of the intestinal subtype
Figure 3 - Disease-free survival. (3a) Disease-free survival according to patient age group. (3b) Disease-free survival in clinical stages 0
and I according to patient age group (YA N=4; OA N=19; E N=13). 3c. Disease-free survival in clinical stages II and III according to patient
age group (YA N=27; OA N=56; E N=23).
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involves a sequence of preneoplastic lesions that take longer
to develop, and therefore, this subtype is more frequently
detected in older individuals.
Differences in TNM stage at diagnosis according to age
group were found in this study. Younger patients more fre-
quently presented with locally advanced and metastatic
disease at diagnosis, which is in agreement with previous
findings (5,29). It is possible that gastric cancer is not con-
sidered as a differential diagnosis in young patients with
gastrointestinal symptoms, which could delay investigation
and diagnosis. Furthermore, the findings might indicate
that gastric cancer has a more aggressive course in young
individuals.
Younger and older patients with gastric cancer had similar
overall cumulative survival rates in our study. Nevertheless,
in our study, YA had the lowest overall 2-year survival rate
(31%). This finding is in agreement with those of other recent
studies (8,9,30,31). However, some studies have reported
worse survival rates among young patients (5,32,33), while
others have found higher survival rates for younger patients
(6,7,18).
Several reasons may explain this inconsistency. First,
definitions of study groups are diverse. In recent studies,
the cut-off age to define young patients has varied from 35
in Smith and Stabile (5) to 50 years in Pisanu et al. (34).
Moreover, definitions of control groups have differed, with
some studies considering two to five groups with consecu-
tive ages and others analyzing two groups with non-
consecutive ages. Second, a small number of young patients,
sometimes fewer than 50 (5,32,34,35), may have contributed
to the reported discrepancies. Third, regional variations in
gastric cancer incidence and mortality rates might be impli-
cated in this difference (1). In Eastern countries, most studies
found no differences (9,30,31) or better survival rates (5,18)
for young patients. Among Western countries, two studies
reported better outcomes for this group (7,35), two found
worse outcomes (5,32), and two detected no differences in
survival rates for YAs (8,34). Finally, different treatment
courses might have contributed to the outcome differences
observed among studies.
After adjusting for CS, the differences in survival were
significant among patients in the CS IV group, in which E
patients had the poorest survival rate (3.2%). In our study,
CS II, III and IV at diagnosis, no surgical treatment and no
chemotherapy were all significantly associated with poorer
prognosis in all patients. For the YA group, only metastatic
disease at diagnosis was a significant prognostic factor,
perhaps because practically all young patients with stage
I-III disease in our sample underwent surgery (32 of 33).
Additionally, there were no differences in disease-free
survival, possibly due to the small number of patients
diagnosed with resectable tumors, especially in the YA
group.
Our study is the first to our knowledge to evaluate
survival rates and prognostic factors in YAs with gastric
cancer in Brazil. Our study limitations include the limited
number of patients and the selection of controls. However,
we provide new and clinically valuable data on a disease
with increasing incidence in YAs, a group in which cancer
may have considerable social and psychological impacts.
In this scenario, young patients were rarely diagnosed with
early stage disease, which is why they tended to have low
survival rates. It remains unclear whether this is due to a
diagnosis delay or more aggressive disease behavior. There-
fore, awareness among YAs should be improved in order to
diagnose gastric cancer at a curable stage.
Table 3 - Hazard ratios of death for all patients and for younger adults.
All patients Younger adults
HR (95% CI) P-value HR (95% CI) P-value
Univariate
Age (ref: Elderly)
Younger adult 0.94 (0.65-1.37) 0.75 -
Older adult 0.66 (0.52-1.02) 0.06 -
Sex (ref. male)
Female 0.95 (0.72-1.27) 0.77 0.94 (0.54-1.63) 0.83
Histology (ref. intestinal)
Diffuse 1.55 (1.07-2.24) 0.02 0.99 (0.24-4.11) 0.99
Mixed 1.00 (0.49-2.07) 0.98 1.79 (0.29-10.80) 0.52
Clinical stage (ref. 0 or I) (Ref. 0, I, II or III)
II or III 3.59 (1.63-7.90) o0.01* -
IV 20.18 (9.18-44.35) o0.01* 6.35 (3.20-12.59) o0.01*
Surgery (ref: yes)
No 5.53 (4.03-7.58) o0.01* 4.16 (2.25-7. 70) o0.01*
Chemotherapy (ref: yes)
No 3.08 (2.13-4.47) o0.01* 3.35 (1.71-7.34) o0.01*
Multivariate
Histology (ref. intestinal)
Diffuse 1.14 (0.75-1.75) 0.52 -
Mixed 1.63 (0.725-3.54) 0.24 -
Clinical stage (ref. 0 and I) Ref. 0, I, II, and III
II or III 13.50 (4.04-45.06) o0.01* -
IV 34.75 (10.07-19.92) o0.01* 4.84 (1.76-13.33) o0.01*
Surgery (ref: yes)
No 1.42 (0.86-2.34) 0.17 1.35 (0.67-2.73) 0.40
Chemotherapy (ref: yes)
No 2.34 (1.35-4.05) o0.01* 1.19 (0.42-3.36) 0.73
*Statistically significant
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There was no difference in the overall survival of YAs
and OAs with gastric cancer. Nevertheless, YAs were more
frequently diagnosed with metastatic disease, the only factor
predictive of death in this age group. These findings suggest
the need for a better approach to diagnose early gastric
cancer in patients aged 40 years or younger.
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